News Related to Lyell Immunopharma

Related coverage linked through entity extraction aliases.

Guardant Health CMO to Resign; Delfi and Singular Name New Leaders

May 02, 2026

Guardant Health said its chief medical officer will resign effective May 8, while Delfi Diagnostics appointed Charles Newton to its board and Singular Genomics named John Stark CEO.

Lyell Immunopharma Doses First Patient in Phase 3 Head-to-Head CAR T-Cell Trial for Lymphoma

Feb 12, 2026

Lyell Immunopharma has initiated dosing in its Phase III PiNACLE – H2H trial, comparing ronde-cel against approved CAR T-cell therapies for relapsed or refractory large B-cell lymphoma in second-line treatment.